Introduction
Cells sense a variety of external signals such as growth factors, hormones and cytokines, as well as environmental conditions like osmolarity, radiation or the presence of xenobiotics. Responses to, both, physiological and environmental stimuli are ultimately mediated by specific signaling cascades that can affect cellular growth, differentiation or survival. One prominent signal transduction cascade that responds to a large variety of physiological and environmental stimuli is constituted by the mitogen-activated protein kinase (MAPK) pathways. In mammalian cells multiple groups of MAPKs have evolved. Best studied are the ERK, p38, and Jun-NH 2 -terminal kinase (JNK) MAPK pathways. All three MAPKs phosphorylate downstream transcription factors and thereby alter gene expression to direct a specific cellular response. The MAPKs are activated by different MAPK kinases (MAPKKs), which themselves respond to MAPKK kinases (MAPKKKs) that are coupled, through additional intermediary factors, to, for example, cell-membranebound receptor proteins or the cytoskeleton (Chang and Karin, 2001; Wada and Penninger, 2004) .
Like physiological hormones, also environmental agents ultimately have to trigger specific signaling events to elicit a specific cellular response. One possibility is the action on components of cellular signaling networks that do not evidently show the features of a receptor molecule, but whose alterations by environmental agents nevertheless have profound effects on cellular signaling. Examples are the inhibition of phosphatases for receptor tyrosine kinases (RTKs) or JNK by UV irradiation, H 2 O 2 , or arsenite, which results in net increased signaling through RTK/MAPK pathways (Cavigelli et al., 1996; Knebel et al., 1996) .
Other xenobiotics such as environmental hormonelike compounds, for example, 'endocrine disruptors', occupy specific ligand-binding sites on intracellular receptors that themselves can act as ligand-dependent transcription factors (Mangelsdorf et al., 1995; Schmidt and Bradfield, 1996; McLachlan, 2001) . As a further addition to complexity, it has to be considered that cellular signaling pathways can interfere with each other synergistically or by mutual inhibition (Noselli and Perrimon, 2000; Herrlich, 2001; de Bosscher et al., 2003) .
The aryl hydrocarbon receptor (AhR) belongs to a family of transcription factors, the Per/AhR/ARNT/ SIM (PAS) proteins with a central PAS homology region, which also includes the hypoxia-inducible factor 1a and mediators of circadian rhythm (Hoffman et al., 1991; Burbach et al., 1992; Ema et al., 1992; Reyes et al., 1992; Dunlap, 1998) . The AhR has gained interest as a physiological developmental factor since AhR knockout mice show defects in the liver, the mammary gland, and the peripheral immune system. AhR was initially identified and is of central interest as mediator of xenobiotica toxicity because it specifically binds nonphysiologic compounds including food mutagens, polycyclic aromatic hydrocarbons (Ah), and polyhalogenated aromatic hydrocarbons (Swanson and Bradfield, 1993) . The latter class of chemicals includes halogenated dibenzo-p-dioxins, collectively called 'dioxins', as well as dibenzofuranes and biphenyls. One of these compounds, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) gained specific interest, both as a major contaminant of the 'Agent Orange' defoliating agent used in the Vietnam war, as well as the toxic agent released during the Seveso herbicide production accident in 1976. Dioxins induce chloracne, are carcinogens and are toxic to the immune and reproductive systems (Suskind, 1985; Couture et al., 1990; Zugerman, 1990; Peterson et al., 1993; vanden Heuvel and Lucier, 1993; Huff et al., 1994) . The AhR mediates most if not all of these toxic effects (Fernandez-Salguero et al., 1996) .
Ligand binding induces AhR translocation from the cytosol to the nucleus. After heterodimerization with aryl hydrocarbon receptor nuclear translocator (ARNT), the AhR/ARNT heterodimer binds to specific response elements (xenobiotic response elements (XREs)) within the promoters of target genes, thus enhancing expression of mainly detoxification enzymes such as cytochrome P450 s (e.g. Cyp1A1).
So far, 'classical' target genes of AhR mostly code for metabolic enzymes and cannot satisfactorily explain the mechanism(s) underlying dioxin poisoning (FernandezSalguero et al., 1995; Schmidt and Bradfield, 1996) . The search for genes relevant for dioxin toxicity revealed the cell cycle inhibitor p27Kip1 as a novel target gene of AhR (Kolluri et al., 1999) . Kip1 induction mediates some of the toxic consequences of dioxin action, such as inhibition of proliferation in the developing thymus and in 5L rat hepatoma cells. AhR-dependent induction of the proapoptotic bax gene is apparently required for ovarian damage inflicted by dioxins (Matikainen et al., 2001) . Other aspects of dioxin toxicity or carcinogenicity cannot easily be explained by the two latter AhR target genes.
In the present study, we investigated the contribution of AhR to induction of AP-1 activity by TCDD. Induction of expression of AP-1 subunits c-jun and cfos by dioxins has been described before (Puga et al., 1992; Hoffer et al., 1996) , but the mechanism of induction and the role of AhR in particular could not be conclusively addressed due to the lack of suitable cell models. We now demonstrate AhR-dependent induction of c-jun. Induction of c-jun occurs by activation of the p38-MAPK pathway and thus differs from the classical mode of AhR-dependent regulation of gene expression by binding of the receptor to its XRE recognition sequences in promoters of regulated target genes. p38-MAPK activation does not depend on ongoing gene expression and does not involve increased phosphorylation of known kinases immediately upstream of p38, for example, SEK1 and MKK3/6. These findings establish a novel principle of AhR action in which AhR leads to proto-oncogene induction by activating 'cross-talk' with the p38-MAPK pathway.
Results

AhR-dependent induction of AP-1 abundance and activity
To analyse the role of the AhR in induction of AP-1 activity by TCDD, we used rat hepatoma cells expressing AhR (5L-cells) or variants thereof that lack the receptor (BP8-AhR À cells; Weiss et al., 1996) . TCDD increases AP-1 activity in 5L-cells as measured both by DNA-binding assays ( Figure 1a ) and by AP-1-dependent reporter gene activation (Figure 1b) . Significantly, TCDD cannot induce AP-1 activity in BP8-AhR À cells (Figure 1b ), indicative of a requirement for the AhR. Increase in AP-1 activity could either be mediated by increased AP-1 subunit expression or by post-translational modifications of pre-existing AP-1 proteins (Vogt, 2001; Weiss and Bohmann, 2004) .
To address whether TCDD activates AP-1 at the level of subunit expression, we analysed its influence on the abundance of c-jun mRNA. TCDD leads to a persistent increase in c-jun mRNA levels ( Figure 1c ) in 5L cells. Furthermore, nuclear run-on experiments show that TCDD enhances the transcriptional rate of c-jun (Figure 1d ). c-jun mRNA is induced with a dose-response curve (Figure 1e , f) that resembles that of other previously identified AhR target genes (Kolluri et al., 1999) . AlphaNaphthoflavone (a-NF) is a structurally unrelated ligand for the AhR that also induces c-jun (Figure 2a) , suggesting that c-jun induction depends on the AhR. To obtain further proof that the AhR mediates the induction of c-jun by TCDD, we compared 5L-cells expressing AhR, their AhR-deficient subclone BP8-AhR À , and BP8-AhR þ cells in which AhR expression was partially restored by reexpression from a retroviral vector. Indeed, induction of c-jun by TCDD strictly depends on the presence of AhR (Figure 1c and 2b) .
Dissociation of Cyp1A1 and c-Jun induction by TCDD
TCDD has previously been shown to induce c-jun mRNA in the mouse hepatoma cell line Hepa 1 (Puga et al., 1992) . In contrast to those previous studies we could not observe c-Jun induction in Hepa 1 cells although the 'classical' target gene cyp1A1 was induced by TCDD (Figure 3) . The lack of c-Jun-induction in the Hepa 1 cell line used in our studies might be explained by differences between different Hepa 1 sublines such as the loss of a permissive factor, which links AhR signaling to c-jun. cyp1A1 is induced by binding of the ligand-activated AhR heterodimerized with ARNT to several so-called XREs in the promoter (Nebert et al., 1993 , Nebert, 1994 . The observed dissociation of Cyp1A1 and c-Jun induction indicates that TCDD induces c-Jun by a different pathway which is functional in 5L cells but not in the Hepa 1 subline used.
Activation of p38-MAPK by TCDD and its dependence on the AhR
Many stimuli which induce c-jun transcription are transduced via activation of MAPK pathways (Leppaä nd Bohmann, 1999; Jochum et al., 2001; Weiss and Bohmann, 2004) . Therefore, we investigated the activation of all three MAPKs (ERK1/2, p38-MAPKs, and JNK1/2) by TCDD. TCDD induces phosphorylation of p38-MAPKs with kinetics similar to c-jun induction (Figure 4a ), but does not enhance phosphorylation of ERKs or JNKs (data not shown) in 5L rat hepatoma cells. Downstream targets of p38-MAPK are transcription factors such as ATF-2, CREB, and Elk-1, which upon phosphorylation enhance gene expression. Indeed, TCDD increases phosphorylation of ATF-2 and CREB (data not shown) and stimulates transcriptional activation by CREB and Elk-1 (Figure 4b ).
To analyse the involvement of AhR in this pathway, we first analysed activation of the p38-MAPK substrate Elk-1 by an Elk-1-responsive reporter gene as a sensitive assay for activation of p38-MAPK. Whereas no Elk-1 Figure 1 (a) TCDD increases DNA-binding activity of AP-1 in 5L cells. Logarithmically growing 5L cells were incubated for 2 h in the presence of 1 nM TCDD or 0.1% DMSO (solvent control), or were treated for 30 min with 100 ng/ml 12-O-tetradacanoylphorbol 13-acetate (TPA), nuclear extracts of these cells were used for electrophoretic mobility shift assays with oligonucleotides containing an AP-1-binding DNA motif. One representative experiment out of two is shown. (b) TCDD activates an AP-1-dependent reporter gene in 5L wild-type cells, but not in AhR-deficient BP8AhR À cells. 1 Â 10 7 logarithmically growing cells were transiently transfected by electroporation with 20 mg of AP-1-responsive À73 coll-luciferase reporter gene plasmid, resuspended in 20 ml medium and distributed to two culture dishes. After 2 h, cells were serum starved (0.5% FCS, 14-18 h) and treated with 1 nM TCDD or 0.1% DMSO as solvent control. Luciferase activity was measured after 24 h and normalized to the protein content. Levels of induction by TCDD in two independent experiments are shown relative to the solvent control (mean þ average deviation (a.d.)). (c) Kinetics of c-jun mRNA induction by TCDD in 5L cells. Subconfluently growing 5L cells were serum starved for 14-18 h and were cultivated for the indicated time periods in the presence of 1 nM TCDD or exposed to either 0.1% DMSO for 5 h or 100 ng/ml TPA for 40 min. For Northern blot analysis, 10 mg poly(A) þ RNA was used. For control of loading, the membrane was rehybridized with a probe directed against glyceraldehyde-3-phosphate-dehydrogenase (GAPDH). One representative experiment out of two is shown. (d) TCDD increases de novo synthesis of c-jun mRNA. 5L cells were incubated for 24 h with 1 nM TCDD or 0.1% DMSO. The isolated nuclei were used for nuclear run-on analysis to determine the de novo mRNA synthesis of c-jun or an unaffected control gene, GAPDH. One representative experiment out of two is shown. (e, f) Dose response of c-jun mRNA induction by TCDD in 5L cells. Logarithmically growing 5L cells were treated for 24 h with the indicated TCDD doses or with 0.1% DMSO. For Northern blot, 2 mg poly(A) þ RNA was used. For quantitative graphic representation, blots were evaluated by a phosphoimager and c-jun mRNA signals were normalized to GAPDH signals. The estimated TCDD dose leading to half-maximal induction (EC 50 ) of c-jun mRNA was determined graphically. One representative experiment out of two is shown AhR regulates c-jun via p38-MAPK C Weiss et al activation is detectable in BP8-AhR À cells, partial Elk-1 activation is found in BP-AhR þ cells, and the degree of Elk-1 activation is increased by additional transient expression of AhR (Figure 4c ). In addition, we compared p38-MAPK phosphorylation in 5L, BP8-AhR À , and BP8-AhR þ cells. In the absence of AhR, TCDD did not induce p38-MAPK phosphorylation (data not shown). However, the levels of AhR in BP8-AhR þ cells, which are low compared to 5L cells (Weiss et al., 1996) , did not suffice to mediate a significant induction of p38-MAPK phosphorylation. This result is in agreement with the outcome of the aforementioned experiments where AhR had to be co-expressed in BP8-AhR þ cells to enhance Elk-1 activation by TCDD. To provide further evidence for an essential role of AhR in activation of p38-MAPK by TCDD, we depleted AhR levels in 5L cells by transfection of small double-stranded inhibitory RNA (siRNA) targeting AhR mRNA and subsequently analysed the phosphorylation status of p38-MAPK in the absence or presence of TCDD. Transfection of AhR-siRNA in 5L cells led to a dramatic decrease in AhR levels (>90%) after 48 h, whereas no effect was observed using a nonspecific control siRNA ( Figure 4d ). As a functional consequence of downregulation of AhR, Cyp1A1 induction by TCDD was significantly reduced (>70%) (Figure 4e , upper panel). Importantly, lowering the amount of AhR strongly diminished TCDD-enhanced p38-MAPK phosphorylation (>70%), thus demonstrating a pivotal role of AhR in the process of p38-MAPK activation by TCDD (Figure 4e , middle panel).
Mechanism of p38-MAPK activation by TCDD
One of the most prominent signaling pathways to activate MAPKs is triggered by growth factor receptors (GFRs). Indeed, TCDD has been reported to influence the expression of growth factors (GFs) like EGF or TGFa in many other experimental systems (Schmidt and Bradfield, 1996) . Therefore, it appears possible that TCDD activates p38-MAPK by increasing the expression and secretion of growth factors.
Medium transfer from TCDD-treated 5L cells onto nontreated BP8-AhR À cells did not increase p38-MAPK phosphorylation, suggesting that TCDD does not increase phosphorylation of p38-MAPKs by an auto-or À -and BP8-AhR þ cells were serum starved for 14-18 h and were cultivated for the indicated time points in the presence of 1 nM TCDD or 0.1% DMSO. Northern blot analysis was performed as described in Figure 1c . One representative experiment out of two is shown Figure 3 Dissociation of c-Jun and Cyp1A1 induction in 5L rat and Hepa 1 mouse hepatoma cells. Subconfluently growing 5L and Hepa 1 cells were serum starved for 14-18 h and were cultivated for an additional 5 h in the presence of 1 nM TCDD or 0.1% DMSO. Cyp1A1 and c-Jun were detected by Western blot analysis with specific antibodies. For a loading control, the membrane was rehybridized with a non-phosphospecific p38-MAPK antibody recognizing all different p38-MAPK isoforms. One representative experiment out of two is shown AhR regulates c-jun via p38-MAPK C Weiss et al paracrine mechanism, for example by induced expression and secretion of GFs (data not shown). Also, the use of chemical inhibitors of GF signaling such as suramine, a GFR inhibitor, or wortmannin, a PI-3 kinase inhibitor, or PP1, a Src-kinase inhibitor, did not interfere with TCDD-induced activation of p38-MAPK (data not shown). Since no indication was found that increased expression or secretion of GFs is required for TCDD-induced p38-MAPK phosphorylation, we next asked whether transcription is required at all to mediate this effect. Unexpectedly, pretreatment of 5L cells with the protein synthesis inhibitor cycloheximide did not abolish activation of p38-MAPKs by TCDD (Figure 5a ). Cycloheximide was effective, as indicated by the complete loss of p27Kip1 induction. Thus, AhR appears to activate p38-MAPK by a mechanism which does not depend on de novo protein synthesis.
To further characterize this novel mechanism of AhR action, we analysed at which level TCDD activates known elements of the p38-MAPK cascade. None of the three known upstream kinases of p38-MAPK, SEK1, MKK3, or MKK6, is activated by TCDD, whereas the translational inhibitor anisomycin serves as a potent positive control (Figure 5b and Supplementary Figure 1 ). Net phosphorylation of a kinase might also be increased by inhibition of dephosphorylation. Such an inhibition of MAPK phosphatases is the mechanism by which the tumor promoter arsenite activates JNK (Cavigelli et al., 1996) . We tested the loss of p38-MAPK phosphorylation after anisomycin induction in the presence or absence of TCDD. Cotreatment of cells with anisomycin and TCDD did not reduce the decline of p38-MAPK phosphorylation, suggesting that there is no major Figure 4 (a) Kinetics of p38-MAPK activation by TCDD. Subconfluently growing 5L cells were serum starved for 12-16 h and were treated for the indicated time with 1 nM TCDD or 0.1% DMSO, respectively. Phosphorylated p38-MAPK was detected by Western blot analysis with a phospho-p38-MAPK-specific antibody. For a loading control, the membrane was rehybridized with a non-phosphospecific p38-MAPK antibody recognizing all different p38-MAPK isoforms. One representative experiment out of two is shown. (b) TCDD treatment increases the transcriptional activity of ELK-1 and ATF-2. Logarithmically growing 5L cells were transfected with 0.5 mg Gal4-UAS-firefly-luciferasereporter gene and 0.5 mg expression vector either coding for GAL-ELK-1 or GAL-ATF-2. At 24 h after treatment with 1 nM TCDD or 0.1% DMSO, firefly luciferase activity was measured. To normalize for transfection efficiency, 0.1 mg expression vector coding for renilla-luciferase was cotransfected. The induction is given as the ratio of the normalized values of TCDD-vs DMSO-treated cells (shown is the mean value7a.d. of two independent experiments carried out in duplicates). (c) Activation of ELK-1 by TCDD is AhR-dependent. Logarithmically growing 5L cells were transfected with 0.5 mg UAS-firefly-luciferase-reporter gene and 0.1 mg expression vector coding for GAL-ELK-1 together with 0.4 mg empty expression vector. To increase the level of AhR in BP8AhR þ cells, the empty expression vector was replaced by 0.4 mg of expression vector coding for AhR (indicated by þ instead of ( þ ) for AhR status). At 24 h after treatment with 1 nM TCDD or 0.1% DMSO, firefly luciferase activity was measured. To normalize for transfection efficiency, 0.1 mg expression vector coding for renilla-luciferase was cotransfected. The induction is given as the ratio of the normalized values of TCDD-vs DMSO-treated cells (shown is the mean value7a.d. of two independent experiments carried out in duplicates). (d, e) Enhanced phosphorylation of p38-MAPK by TCDD is AhR-dependent. (d) 8 Â 10 4 cells/well were seeded onto a 24-well plate, cultured for 24 h to reach 80-90% confluency and were transfected with 20 pmol of AhR or control siRNAs. At 48 h post transfection, total cell extracts were prepared and AhR was detected by Western blot analysis with an anti-AhR antibody. For a loading control, the membrane was rehybridized with a non-phosphospecific p38-MAPK antibody. (e) Cells were seeded and transfected as described above (d) and treated for 5 h with 1 nM TCDD or 0.1% DMSO. Total cell extracts were subjected to Western blot analysis. The membrane was cut and hybridized with anti-Cyp1A1-(upper panel) or anti-phospho-p38 MAPK antibody (middle panel). The blot was stripped and reprobed with anti-p38 MAPK antibody to control for equal loading (lower panel). One representative experiment out of two is shown. Levels of Cyp1A1 protein are expressed as % of untransfected, TCDD-stimulated cells. Induction of p38-MAPK phosphorylation by TCDD is expressed as x-fold of the corresponding unstimulated control values. Signals obtained with anti-Cyp1A1-and anti-phospho-p38-MAPK antibodies were normalized to the corresponding signals obtained with a non-phosphospecific p38-MAPK antibody AhR regulates c-jun via p38-MAPK C Weiss et al influence of TCDD on p38-MAPK dephosphorylation (Figure 5c ).
Summarizing the results, we postulate an unconventional mode of AhR action in p38-MAPK activation, which appears to induce a novel kinase activity directed towards p38-MAPK independently of de novo protein synthesis.
p38-MAPK activity is required for TCDD to induce c-Jun expression
Having established that TCDD can activate p38-MAPK, we wanted to investigate whether this is the cause or at least contributes to c-Jun induction. If so, c-Jun induction should follow p38-MAPK activation. Indeed, in 5L rat hepatoma cells that show activation of p38-MAPK TCDD induces c-Jun (Figures 3 and 6a) , whereas in the Hepa 1 mouse hepatoma subline in which TCDD fails to activate p38-MAPK induction of c-Jun does not occur (Figures 3 and 6a) . To prove that p38-MAPK activity is required to induce c-Jun by TCDD, we made use of two specific inhibitors of p38-MAPK. Pretreatment with each of the two inhibitors drastically reduced c-Jun but not Cyp1A1 induction by TCDD, showing the essential role of p38-MAPK in the novel TCDD-induced pathway to c-Jun induction (Figure 6b ).
Discussion
Studies in AhR knockout mice have shown that AhR mediates the toxicity of dioxins and is essential for proper postnatal liver development (FernandezSalguero et al., 1995 (FernandezSalguero et al., , 1996 . Substantial parts of the required AhR-controlled genetic programs are, however, yet unknown. In the present attempt to identify novel pathways of AhR-dependent control of genetic The known kinases of p38-MAPK are not activated by TCDD. Logarithmically growing 5L cells were treated for 5 h with 1 nM TCDD or 0.1% DMSO, or for 20 min with anisomycin (An., 10 mg/ ml). Phosphorylated SEK1 or MKK3/6 was detected with a phospho-SEK-or phospho-MKK3/6-specific antibody (n.s.: nonspecific). For loading control, a part of the gel was stained with Coomassie-Blue (not shown). One representative experiment out of two is shown. (c) TCDD does not inhibit dephosphorylation of p38-MAPK. Logarithmically growing 5L cells were treated for 5 h with 1 nM TCDD or 0.1% DMSO. Anisomycin (An., 10 mg/ml) was added for the indicated time as well before cells were harvested, as illustrated in the scheme. Phosphorylated p38-MAPK was detected with a phospho-p38-MAPK-specific antibody. Note that p38-MAPK phosphorylation after TCDD treatment alone is negligible compared to the strong p38-MAPK activation by anisomycin (data not shown). For loading control a part of the gel was stained with Coomassie-Blue (not shown). One representative experiment out of two is shown Figure 6 (a) Phosphorylation of p38-MAPK correlates with c-Jun induction (see Figure 3) . Subconfluently growing 5L and Hepa 1 cells were serum starved for 14-18 h and were cultivated for an additional 5 h in the presence of 1 nM TCDD or 0.1% DMSO. Western blot analysis was performed as in Figure 4a . One representative experiment out of two is shown. (b) Inhibition of p38-MAPK by SB202190 or SB203580 prevents induction of c-Jun but not of Cyp 1A1 by TCDD. Subconfluently growing 5L cells were serum starved for 14-18 h and were cultivated for an additional 5 h in the presence of 1 nM TCDD or 0.1% DMSO, or were pretreated with either 25 mM SB 202190 or SB203580 for 15 min before addition of 1 nM TCDD. Western blot analysis was performed as described in Figure 3 . One representative experiment out of two is shown. Note the somewhat enhanced inhibition of TCDD-induced c-Jun induction by SB202190 compared to SB203580, which is in line with the enhanced efficacy of SB202190 in inhibiting p38-MAPK activity (Supplementary Figure 2) programs, we have shown that transcription of the proto-oncogene c-jun is activated by AhR. Induction of c-jun expression depends on a novel AhR-dependent mechanism of p38-MAPK activation independent of the hitherto known kinases upstream of p38-MAPK or inhibition of p38-MAPK dephosphorylation.
The AhR ligand TCDD had been found to induce cjun expression before (Puga et al., 1992) , but the role of AhR could not be conclusively shown due to the lack of suitable cell culture models. By using 5L-cells expressing AhR, their AhR-deficient subclone BP8-AhR À , and BP8-AhR þ cells in which AhR was re-expressed, we now show that there clearly is an AhR-dependent pathway to activation of c-jun expression by the AhR ligand TCDD (Figures 1c and 2b) .
In addition, we found that TCDD induces c-Jun only in 5L rat but not in the Hepa 1 mouse hepatoma line used (Figure 3 ). This comparison indicates that induction of c-jun depends on a mechanism of TCDD action different from activation of XRE-dependent target genes since the latter is functional in both of the cell lines. Since many stimuli induce c-jun transcription via MAPK pathways, we asked whether TCDD might activate either JNK, p38-MAPK, or ERKs. In fact, we found that p38-MAPK (Figure 4a ), but not JNKs or ERKs, is activated by TCDD in an AhR-dependent fashion. The kinetics of p38-MAPK phosphorylation paralleled the increase in c-jun mRNA levels (Figures 1c  and 4a ). In the Hepa 1 cell line used, absence of p38-MAPK activation correlated with a lack of c-Jun induction despite the presence of functional AhR (Figures 3 and 6a) . Finally, inhibition of p38-MAPK activity by two different inhibitors drastically diminished induction of c-Jun in 5L cells by TCDD, showing that induction of c-Jun by the AhR is dependent on p38-MAPK (Figure 6b ).
Since activation of p38-MAPK by TCDD is independent of new protein synthesis, AhR most likely interacts with other proteins to induce p38-MAPK phosphorylation (Figure 5a ). This raises the question at which level AhR acts on the p38-MAPK pathway. The cytoplasmic tyrosine kinase c-Src has been implicated in the cross-talk of nuclear receptors, such as the estrogen receptor, with ERKs and activation of c-Src by AhR has been postulated (Enan and Matsumura, 1995; Migliaccio et al., 1996 Migliaccio et al., , 1998 . However, an inhibitor of c-Src, PP1, failed to block p38-MAPK activation by TCDD indicating that c-Src does not mediate AhR action on p38-MAPK. The MAPKKs, MKK3/6 and SEK1, which directly phosphorylate p38-MAPK, were not activated by AhR, excluding the possibility that AhR would act on a known p38-MAPK kinase. Also, the inhibition of p38-MAPK inactivation by dephosphorylation could result in a net accumulation of activated p38-MAPK as found in the case of JNK activation by arsenite (Cavigelli et al., 1996) . This possibility, however, also does not appear to be a likely explanation for p38-MAPK activation, since no inhibition of p38-MAPK dephosphorylation could be demonstrated (Figure 5c ). Also, direct binding of AhR to p38-MAPK and activation by a hitherto unknown kinase activity could be considered. This is not likely either because co-immunoprecipitation studies failed to show a complex between AhR and p38-MAPK (data not shown). Furthermore, such a mechanism of activation could be expected to occur in all cell lines expressing AhR and p38-MAPK. However, we found high cell type specificity with respect to p38-MAPK activation, for example, when comparing the Hepa 1 mouse and 5L rat hepatoma cell lines, despite the presence of functional AhR and p38 in both cell lines (Figure 6a) .
Considering the lack of obvious explanations, p38-MAPK activation may require (an) intermediate factor(s) coupling AhR to p38-MAPK that is (are) only present in some cell types such as 5L cells but not in others such as the Hepa 1 strain used. Such an intermediary factor could be itself a novel MAPKK for p38-MAPK. Alternatively, an intermediary factor might serve as an adaptor protein between AhR and p38-MAPK, that facilitates formation of a ternary complex in which p38 is activated. Recently, the first pathway of p38-MAPK activation independent of its upstream MAPKKs has been discovered. The transforming growth factor b-activated protein kinase 1 (TAK1)-binding protein directly binds to p38a, thereby enhancing its kinase activity (Ge et al., 2002) . This or similar proteins may be candidates to couple AhR to p38-MAPK.
Consequences of p38-MAPK activation by TCDD are increased activities of the transcription factors ATF-2 and ELK-1 (Figure 4b ). Enhanced transcription of c-jun (Figures 1c, d ) has been linked to p38-MAPK activity, which, presumably, acts on ATF-2/c-Jun heterodimers regulating the promoter of c-jun (Marinissen et al., 2001; van Dam and Castellazzi, 2001 ).
Here, we have shown that AhR can increase the mRNA and protein levels of the proto-oncogene c-Jun. Transcriptional activity of c-Jun is negatively regulated by binding to a repressor complex composed of histone deacetylase 3 and additional co-repressors (Weiss et al., 2003; Ogawa et al., 2004) . Constitutively increased c-Jun levels relieve inhibition by exceeding the limited amount of repressor constituents, thus increasing transcription activation by c-Jun. Therefore, TCDD might chronically enhance c-Jun activity by inducing c-jun transcription, resulting in persistently elevated levels of c-Jun which eventually will deliberate c-Jun from suppression. Proper expression and activity of c-Jun and other AP-1 subunits is critical for many cellular processes such as differentiation, proliferation or apoptosis (Leppa¨and Bohmann, 1999; Jochum et al., 2001) , and therefore it is likely that the p38-MAPK pathway, in addition to activation of specific transcription factors, mediates aspects of dioxin toxicity and carcinogenicity. One of the most prominent consequences of dioxin poisoning is increased tumor incidence. A critical role of c-Jun in tumorigenesis has been suggested since it cooperates with and is required for oncogenic ras to transform fibroblasts. Indeed, recent studies proved an essential contribution of c-Jun in chemically and oncogenic ras induced liver and skin tumors, respectively (reviewed in Weiss and Bohmann, 2004 ).
In conclusion, we have shown an AhR-induced and p38-MAPK-dependent pathway leading to increased expression and activity of c-Jun. Activation of p38-MAPK is not mediated through induced gene expression, but by a novel mode of 'cross-talk' between the AhR and MAPKs on the level of p38-MAPK or a hitherto unknown kinase upstream of p38-MAPK. These findings may help to explain the role of AhR in cell-type-specific physiological functions, as well as in mediating the toxicity or carcinogenicity of nonphysiological AhR ligands such as dioxins.
Materials and methods
Cell culture and biochemical analysis
Cell culture conditions and treatment of cells with TCDD have been described (Weiss et al., 1996) . Hepa 1 were purchased from ATCC. For Western blot analysis, whole cell extracts were prepared in denaturing SDS sample buffer. Antibodies (from Santa Cruz, if not stated otherwise) were rabbit antiKip1 (C-19), rabbit anti-ERK (K-23), rabbit anti-JNK (Fl), rabbit anti-c-Jun (H79), rabbit anti-p38 (C-20), and goat antiCyp1A1 (G-18). Rabbit phospho-specific-anti-ERK, -anti-p38, -anti-JNK, -anti-SEK 1, -anti-MKK3/6, -anti-CREB, andanti-ATF2 were purchased from Cell Signalling and rabbit anti-AhR was ordered from Biomol. For a more sensitive detection of c-Jun induction by TCDD, cells were serum starved since serum regulates basal c-Jun expression. Besides monitoring induction of c-Jun by TCDD in serum-starved cells, we were also able to detect c-Jun induction after TCDD exposure in cells maintained in normal growth medium although, as expected, basal c-Jun levels were elevated and thus inducibility by TCDD was reduced (data not shown). Northern blots were usually performed with 10 mg of poly(A) þ RNA. The amount of RNA loaded in each lane was controlled by hybridization with a GAPDH probe. Nuclear run-on analysis has been described (Kolluri et al., 1999) . Nuclear extracts were prepared and used in EMSAs as previously described (Bender et al., 1998) . Briefly, cells were lysed in 100 ml of lysis buffer (10 mM HEPES, pH 7.9, 1 mM EDTA, 60 mM KCl, 0.5% Nonidet P-40, 1 mM DTT, 1 mM PMSF). After 5 min on ice, nuclei were sedimented at 1200 g for 5 min. The nuclei were washed with lysis buffer without NP-40 and resuspended in 100 ml of nuclear buffer (250 mM Tris-HCl, pH 7.8, 60 mM KCl, 1 mM DTT, 1 mM PMSF). Nuclei were lysed by three cycles of freezing and thawing in liquid nitrogen and ice. Binding was performed in a volume of 20 ml with 5-6 mg nuclear protein in a buffer containing 12 mM HEPES, pH 7.8, 62.5 mM Tris-HCl, pH 7.8, 60 mM KCl, 0.6 mM EDTA, 12% glycerol, 5 mM DTT, 2 mg BSA, and 1 mg poly (dI-dC). Approximately 10 fmol (100 000 c.p.m.) of 32 Pradiolabeled double-stranded oligonucleotide (5 0 -AGCTTAA GCATGAGTCAGACAGCCG-3 0 , 'TRE' or 5 0 -TCGAGCCT CCAGGCTCTTCTCACGCAACTCCGGGGTAC-3 0 , 'XRE') was used per reaction. Resultant DNA-protein complexes were resolved on 5% polyacrylamide gels and detected by autoradiography.
Reporter gene assay, siRNA and transient transfection studies
Cells were transfected at 50-70% confluency either by electroporation (Weiss et al., 1996) or by lipofection with TFX-50 (Promega). At 14-16 h after transfection, cells were incubated in 1 nM TCDD or 0.1% DMSO as a solvent control. Transfection efficiency was controlled by co-transfection with 100 ng ubiquitin promoter-driven renilla luciferase reporter construct (Werling et al., 2001) . At 24 h after treatment, cells were washed twice with PBS and lysed with passive lysis buffer (Promega). The normalized values are shown representing the ratio of firefly luciferase activities to renilla luciferase activities.
For transfection of AhR and control siRNAs, 8 Â 10 4 cells/ well (24-well plate) were seeded and cultured for 24 h in DMEM/10% FCS to reach 80-90% confluency. Transfection was performed in a total volume of 600 ml containing 20 pmol AhR or control siRNAs and 1 ml of Lipofectamine 2000 according to the manufacturer's instructions (Invitrogen). After 48 h, cells were exposed for 5 h to 1 nM TCDD. Total cell extracts were prepared and subjected to Western blot analysis. The blot was cut into three pieces and hybridized with antiAhR-, anti-Cyp1A1-, or anti-phospho-p38 MAPK antibodies. The blot was stripped and reprobed with anti-p38 MAPK antibody to control for equal loading. Quantification of Western blot signals was performed with NIH Image (version 1.61). AhR and control siRNAs were purchased from Ambion with the following sequences: AhR-siRNA (directed against rat AhR mRNA sequence [gi: 6978474] from position 825 to 845):
CGUUAGAUGUUCCUCUGUGtt (sense sequence) and CACAGAGGAACAUCUAACGtt (antisense sequence); control siRNA (directed against mRNA encoding the red fluorescence protein DsRed from the coral Discosoma): AGUUCC AGUACGGCUCCAAtt (sense sequence) and UUGGAGCC GUACUGGAACUtt (antisense sequence).
Plasmids
Expression and reporter gene plasmids pSG-GAL4-Elk-1 (kindly provided by P Shaw), pGAL-ATF-2-N (kindly provided by H van Dam), pCMV5-AhR (Weiss et al., 1996) , À73/ þ 63Coll-luc (kindly provided by A Cato), and pG5.E4-D38lux3 (kindly provided by P Shaw).
